We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Innovative Breast Biopsy Marker Enhances Ultrasound Visibility during Surgical Procedures

By MedImaging International staff writers
Posted on 24 Aug 2023
Print article
Image: The new HydroMARK Plus Breast Biopsy Site Marker is an innovation for tissue marker displacement (Photo courtesy of Mammotome)
Image: The new HydroMARK Plus Breast Biopsy Site Marker is an innovation for tissue marker displacement (Photo courtesy of Mammotome)

For core biopsy procedures, ultrasound continues to be preferred due to its ability to provide real-time visualization of both the lesion and the needle. This capability allows clinicians to make quick decisions that benefit the patient and enhance procedural efficiency. In ultrasound-guided breast biopsies, user-friendly devices capable of obtaining high-quality tissue samples can lead to confident outcomes. Now, an innovative breast biopsy marker can enhance ultrasound visibility, simplify locating, and prevent displacement during surgical interventions. This new solution addresses the need for a nickel-free, long-term, ultrasound-visible clip that will not displace during surgical procedures.

Mammotome (Cincinnati, OH, USA), a part of the Danaher Corporation, has rolled out the HydroMARK Plus Breast Biopsy Site Marker to expand its existing HydroMARK tissue marker portfolio. The HydroMARK Plus marker offers the same unmatched advantages as the original HydroMARK tissue marker line, which features exclusive hydrogel technology. This hydrogel-based carrier hydrates more than 200% of its original size within 24 hours, becoming distinctly anechoic. Its effects persist for up to 12 months, ensuring long-term ultrasound visibility, even in patients undergoing neoadjuvant chemotherapy (NACT).

When combined with the HydroMARK Plus shape, a portion of which extends outside of the carrier, there is a significant improvement in visibility and ease of locating under ultrasound, as compared to the original HydroMARK markers. The distinctive marker shape, referred to as "dragonfly," features 'wings' that anchor to the tissue, preventing displacement from the biopsy site during surgical excision. This design supports surgeons in attaining their procedural objectives. The HydroMARK Plus Breast Biopsy Site Marker is likely to become available to U.S. clinicians by the end of 2023, with subsequent plans for expansion to Canada and select countries worldwide.

"With patients at the center of everything we do, we are proud to bring an innovative product to clinicians that advances breast care," said Sarah Moore, President of Mammotome. "We expect the HydroMARK Plus marker to significantly improve visibility at placement and add surgical efficiency, which will benefit radiologists, surgeons and the patients they serve."

Related Links:
Mammotome 

Gold Supplier
Conductive Gel
Tensive
Gold Supplier
128 Slice CT Scanner
Supria 128
New
Color Doppler Ultrasonic Scanner
TBC-6000N
New
Multi-Purpose C-Arm System
Celex

Print article
Sun Nuclear -    Mirion

Channels

Radiography

view channel
Image: The AI model improves tumor removal accuracy during breast cancer surgery (Photo courtesy of UNC School of Medicine)

AI Model Analyzes Tumors Removed Surgically in Real-Time

During breast cancer surgery, the surgeon removes the tumor, also known as a specimen, along with a bit of the adjacent healthy tissue to ensure all cancerous cells are excised. This specimen is then X-rayed... Read more

MRI

view channel
Image: MRI screen-detected breast cancers have been found to be most often invasive cancers (Photo courtesy of 123RF)

MRI Screen-Detected Breast Cancers Are Mostly Invasive

Annual breast MRI screening is advised for patients with a lifetime breast cancer risk exceeding 20%. There exists robust data about the features of mammographic screen-detected breast cancers, although... Read more

Nuclear Medicine

view channel
Image: An AI model can evaluate brain tumors on PET (Photo courtesy of Freepik)

AI Model for PET Imaging Determines Patient Response to Brain Tumor Treatments

The assessment of changes in metabolic tumor volume (MTV) through PET scans using specific radiotracers like F-18 fluoroethyl tyrosine (FET) plays a vital role in evaluating the treatment response in patients... Read more

General/Advanced Imaging

view channel
Image: Annalise Enterprise CTB acts like a ‘second pair of eyes’ for radiologists (Photo courtesy of Annalise.ai)

Deep Learning System Boosts Radiologist Accuracy and Speed for Head CTs

Non-contrast computed tomography of the brain (NCCTB) is a commonly employed method for identifying intracranial pathology. Despite its frequent use, the complex scan outcomes are prone to being misunderstood.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.